Rigel Pharmaceuticals Q3 2023 Gaap EPS $(0.03) Beats $(0.07) Estimate, Sales $28.13M Beat $27.20M Estimate
Portfolio Pulse from saritha@benzinga.com
Rigel Pharmaceuticals reported Q3 2023 GAAP EPS of $(0.03), beating the $(0.07) estimate by 57.14%. This is a 72.73% increase over the same period last year. Sales were $28.13M, beating the $27.20M estimate by 3.43%, a 25.54% increase over last year.
November 07, 2023 | 10:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rigel Pharmaceuticals' Q3 2023 results exceeded estimates, with a 72.73% YoY increase in EPS and a 25.54% YoY increase in sales.
Rigel Pharmaceuticals reported better than expected Q3 2023 results, with both EPS and sales beating estimates. This positive financial performance could lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100